The role of the lipogenic pathway in the development of hepatic steatosis

Diabetes and Metabolism

Volumn 34, Issue 6 PART 2, 2008, Pages 643-648

  Postic, C ^a,b   Girard, J ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

Hepatic steatosis; Insulin resistance; Lipogenesis; NAFLD; Review

Indexed keywords

LIPID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL; DISEASE COURSE; DISEASE MODEL; FAT INTAKE; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; METABOLISM; MOUSE; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; DIETARY FATS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; LIPIDS; LIVER CIRRHOSIS; MICE; NECROSIS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 62749188867     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(08)74599-3     Document Type: Article

References (54)

1. Abdelmalek MF, Diehl AM. Nonalcoholic Fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91:1125-49.
2. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008;60:311-57.
3. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-9.
4. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
5. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-76.
6. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
7. Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 2005;73:65-75.
8. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005;36:232-40.
9. Voshol PJ, Haemmerle G, Ouwens DM, Zimmermann R, Zechner R, Teusink B, et al. Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipasedeficient mice. Endocrinology 2003;144:3456-62.
10. Park SY, Kim HJ, Wang S, Higashimori T, Dong J, Kim YJ, et al. Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart. Am J Physiol Endocrinol Metab 2005;289:E30-9.
11. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51.
12. Foufelle F, Ferré P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose:a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002;366:377-91.
13. Iynedjian PB, Ucla C, Mach B. Molecular cloning of glucokinase cDNA. Developmental and dietary regulation of glucokinase mRNA in rat liver. J Biol Chem 1987;62:6032-8.
14. Vaulont S, Munnich A, Decaux JF, Kahn A. Transcriptional and posttranscriptional regulation of L-type pyruvate kinase gene expression in rat liver. J Biol Chem 1986;261:7621-5.
15. Elshourbagy NA, Near JC, Kmetz PJ, Sathe GM, Southan C, Strickler JE, et al. Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. J Biol Chem 1990;265:1430-5.
16. Katsurada A, Iritani N, Fukuda H, Matsumura Y, Nishimoto N, Noguchi T, et al. Effects of nutrients and hormones on transcriptional and post-transcriptional regulation of acetyl-CoA carboxylase in rat liver. Eur J Biochem 1990;190:435-41.
17. Katsurada A, Iritani N, Fukuda H, Matsumura Y, Noguchi T, Tanaka T. Effects of nutrients and insulin on transcriptional and post-transcriptional regulation of glucose-6-phosphate dehydrogenase synthesis in rat liver. Biochim Biophys Acta 1989;1006:104-10.
18. Jakobsson A, Westerberg R, Jacobsson A. Fatty acid elongases in mammals:their regulation and roles in metabolism. Prog Lipid Res 2006;45:237-49.
19. Ntambi JM. Dietary regulation of stearoyl-CoA desaturase 1 gene expression in mouse liver. J Biol Chem 1992;267:10925-30.
20. Coleman RA, Lee DP. Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res 2004;43:134-76.
21. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance:lessons from genetically engineered mice. J Clin Invest 2008;118:829-38.
22. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006;116:817-24.
23. Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 2002;297:240-3.
24. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 2002;99:11482-6.
25. Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M, et al. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 2005;115:1030-8.
26. Gutierrez-Juarez R, Pocai A, Mulas C, Ono H, Bhanot S, Monia BP, et al. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J Clin Invest 2006;116:1686-95.
27. Chu K, Miyazaki M, Man WC, Ntambi JM. Stearoyl-coenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol 2006;26:6786-98.
28. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007;13:1193-202.
29. Flowers MT, Ntambi JM. Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol 2008;19:248-56.
30. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997;244:1-14.
31. Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, Liu X, et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab 2007;6:484-96.
32. Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein- 1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005;87:81-6.
33. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-14.
34. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of SREBP-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA 2004;101:11245-50.
35. Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab 2007;5:73-9.
36. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000;14:2831-8.
37. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X recep-tor agonists in mice with selective deficiency of sterol regulatory element- binding protein-1c. J Biol Chem 2002;277:9520-8.
38. Dentin R, Pegorier JP, Benhamed F, Foufelle F, Ferre P, Fauveau V, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 2004;279(19):20314-26.
39. Cha JY, Repa JJ. The Liver X Receptor (LXR) and Hepatic Lipogenesis: The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007;282:743-51.
40. Denechaud PD, Bossard P, Lobaccaro JM, Millatt L, Staels B, Girard J, et al. ChREBP, but not LXRs, is required for the induction of glucose- regulated genes in mouse liver. J Clin Invest 2008;118:956-64.
41. Decaux JF, Antoine B, Kahn A. Regulation of the expression of the L-type pyruvate kinase gene in adult rat hepatocytes in primary culture. J Biol Chem 1989;264:11584-90.
42. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, et al. Liver-Specific Inhibition of ChREBP Improves Hepatic Steatosis and Insulin Resistance in ob/ob Mice. Diabetes 2006;55:2159-70.
43. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006;4:107-10.
44. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5- phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate- activated protein phosphatase in rat liver. Proc Natl Acad Sci USA 2003;100:5107-12.
45. Tsatsos NG, Towle HC. Glucose activation of ChREBP in hepatocytes occurs via a two-step mechanism. Biochem Biophys Res Commun 2006;340:449-56.
46. Li MV, Chang B, Imamura M, Poungvarin N, Chan L. Glucosedependent transcriptional regulation by an evolutionarily conserved glucose-sensing module. Diabetes 2006;55:1179-89.
47. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008;118:2992-3002.
48. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-74.
49. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003;100:3077-82.
50. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, Hubbard BK, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 2007;6: 69-78.
51. Minehira K, Young SG, Villanueva CJ, Yetukuri L, Oresic M, Hellerstein MK, et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res 2008;49:2038-44.
52. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 2007;20:351-8.
53. Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res 2008 (in press).
54. Robichon C, Girard J, Postic C. Can the hyperactivity of lipogenesis cause hepatic steatosis? A role for ChREBP. Med Sci (Paris) 2008;24:841-6.